Bender Robert & Associates
- SEC CIK
- 0000894300
- Latest filing
- Jul 30, 2026
URGN holding history
UroGen Pharma Ltd. in every 13F filed by Bender Robert & Associates, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
URGN overviewAll 13F holders of URGNFull Q2 2026 holdings
- Shares (Q2 2026)
- 0
- Sold out in Q2 2026
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 12
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 0 | $0 | 0.0% | −34,701−100.0% | Sold out | Holders |
| Q1 2026 | 34,701 | $623.9K | 0.1% | +34,701 | New | Holders |
| Q4 2025 | 0 | $0 | 0.0% | −34,701−100.0% | Sold out | Holders |
| Q3 2025 | 34,701 | $692.3K | 0.1% | 00.0% | Unchanged | Holders |
| Q2 2025 | 34,701 | $475.4K | 0.1% | +34,701 | New | Holders |
| Q1 2025 | 0 | $0 | 0.0% | −34,701−100.0% | Sold out | Holders |
| Q4 2024 | 34,701 | $369.6K | 0.1% | +34,701 | New | Holders |
| Q2 2024 | 0 | $0 | 0.0% | −34,701−100.0% | Sold out | Holders |
| Q1 2024 | 34,701 | $520.5K | 0.1% | 00.0% | Unchanged | Holders |
| Q4 2023 | 34,701 | $520.5K | 0.1% | 00.0% | Unchanged | Holders |
| Q3 2023 | 34,701 | $486.2K | 0.1% | 00.0% | Unchanged | Holders |
| Q2 2023 | 34,701 | $359.2K | 0.1% | 00.0% | Unchanged | Holders |
| Q1 2023 | 34,701 | $320.6K | 0.1% | +34,701 | New | Holders |
| Q4 2022 | 0 | $0 | 0.0% | −41,131−100.0% | Sold out | Holders |
| Q3 2022 | 41,131 | $342.0K | 0.1% | 00.0% | Unchanged | Holders |
| Q2 2022 | 41,131 | $337.0K | 0.1% | +41,131 | New | Holders |
| Q2 2021 | 0 | $0 | 0.0% | −31,131−100.0% | Sold out | Holders |
| Q1 2021 | 31,131 | $606.0K | 0.2% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.